While Axsome Therapeutics Inc has underperformed by -5.23%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AXSM fell by -2.03%, with highs and lows ranging from $105.00 to $64.11, whereas the simple moving average jumped by 0.15% in the last 200 days.
On December 31, 2024, Mizuho Reiterated Axsome Therapeutics Inc (NASDAQ: AXSM) to Outperform. A report published by Wells Fargo on September 03, 2024, Initiated its previous ‘Overweight’ rating for AXSM. BofA Securities also Upgraded AXSM shares as ‘Buy’, setting a target price of $106 on the company’s shares in a report dated August 06, 2024. Needham Initiated an Buy rating on July 22, 2024, and assigned a price target of $130. Morgan Stanley April 29, 2024d its ‘Equal-Weight’ rating to ‘Overweight’ for AXSM, as published in its report on April 29, 2024. Robert W. Baird’s report from March 19, 2024 suggests a price prediction of $108 for AXSM shares, giving the stock a ‘Outperform’ rating. UBS also rated the stock as ‘Buy’.
Analysis of Axsome Therapeutics Inc (AXSM)
Further, the quarter-over-quarter increase in sales is 81.27%, showing a positive trend in the upcoming months.
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of Axsome Therapeutics Inc’s future performance, with equity being one of the most critical indicators. The goal here is to ensure that your current return on equity of -171.61% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 2.37, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and AXSM is recording an average volume of 622.46K. On a monthly basis, the volatility of the stock is set at 5.18%, whereas on a weekly basis, it is put at 5.96%, with a loss of -0.62% over the past seven days. Furthermore, long-term investors anticipate a median target price of $133.29, showing growth from the present price of $84.60, which can serve as yet another indication of whether AXSM is worth investing in or should be passed over.
How Do You Analyze Axsome Therapeutics Inc Shares?
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 18.28%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 79.23% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
AXSM shares are owned by institutional investors to the tune of 79.23% at present.
